Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 611-618

  Shao, Qin ^a   Shen, Ling Hong ^a   Hu, Liu A ^a   Pu, Jun ^a   Jing, Qing ^b   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Atherosclerosis; Atorvastatin; COX 2; Macrophages; oxLDL

Indexed keywords

ATORVASTATIN; CYCLOOXYGENASE 2; I KAPPA B ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TIME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SHAPE; CHEMOKINES; CYCLOOXYGENASE 2; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; I-KAPPA B PROTEINS; INFLAMMATION; LIPOPROTEINS, LDL; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; PYRROLES;

MURINAE;

EID: 84855523413     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23388     Document Type: Article

References (36)

1. Ahn E, Luk A, Mezody M, Horlick E, Ross H, Butany J. 2009. Early morphological changes of an Amplatzer Septal Occluder explanted at heart transplant. Cardiovasc Pathol 18:57-60.
2. Baeuerle PA, Henkel T. 1998. IB: A specific inhibitor of the NF-κB transcription factor. Science 242:540-546.
3. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. 2002. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105:1816-1823. (Pubitemid 34408892)
4. Burleigha ME, Babaevb VR, Yanceyb PG, Majorb AS, McCalebb JL, Oatesa JA, Morrowa JD, Faziob S, Lintona MF. 2005. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39:443-452.
5. Corsini A. 2000. Fluvastatin: Effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 5:161-175. (Pubitemid 30483493)
6. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. 1998. Cyclooxygenase in biology and disease. FASEB J 12:1063-1073. (Pubitemid 28418937)
7. Gotto AM. 2003. Treating hypercholesterolemia: Looking forward. Clin Cardiol 26:I21-28.
8. Guha M, Mackman N. 2001. LPS induction of gene expression in human monocytes. Cell Signal 13:85-94. (Pubitemid 32222977)
9. Habib A, Shamseddeen I, Nasrallah MS, Antoun TA, Nemer G, Bertoglio J, Badreddine R, Badr KF. 2007. Modulation of COX-2 expression by statins in human monocytic cells. FASEB J 21:1665-1674. (Pubitemid 46855612)
10. Hansson GK. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695.
11. Henkel T, Machleidt T, Nantermet PV, Alkalay I, Kronke M, Ben-neriah Y, Baeuerle PA. 1993. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 365:182-185. (Pubitemid 23282067)
12. Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Díaz C, Hernández G, Egido J. 2002. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160:49-58. (Pubitemid 34082716)
13. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. 2007. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 49:376-383. (Pubitemid 47000312)
14. Kirii H, Niwa T, Yamada Y. 2003. Lack of Interleukin-1b decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 23:656-660. (Pubitemid 36438080)
15. Kiyan J, Kusch A, Tkachuk S, Krämer J, Haller H, Dietz R, Smith G, Dumler I. 2007. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: Role for the urokinase receptor. Atherosclerosis 195:254-261. (Pubitemid 350087953)
16. Koh KK. 2000. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657.
17. Laufs U, Böhm TM. 2005. Cardiac effects of statins-Advancements and open questions. Cardiovasc Res 66:427-429. (Pubitemid 40725754)
18. Lee JY, Kim JY, Lee YG, Rhee MH, Hong EK, Cho JY. 2008. Molecular mechanism of macrophage activation by exopolysaccharides from liquid culture of Lentinus edodes. J Microbiol Biotechnol 18:355-364.
19. Liang SL, Liu HL, Zhou A. 2006. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol 177:651-656. (Pubitemid 43939179)
20. Liao JK. 2005. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F-33F. (Pubitemid 41207730)
21. Liao JK, Laufs U. 2005. Pleriotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89-118.
22. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, Caterina R. 2010. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase- 9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 86:311-320.
23. May MJ, Acquisto FD, Madge LA, Glockner J, Pober JS, Ghosh S. 2000. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the I kappaB kinase complex. Science 289:1550-1554.
24. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. 1999. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci 96:272-277. (Pubitemid 29036089)
25. Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. 2007. High glucoseboosted inflammatory response to lipopolysaccharide are suppressed by statin. J Periodontal Res 42:31-38.
26. Palinski W, Napoli C. 2002. Unraveling pleiotropic efects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 22:1745-1750. (Pubitemid 35315755)
27. Paumelle R, Staels B. 2007. Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. Circ Res 100:1394-1395. (Pubitemid 46834749)
28. Rosenson RS, Tangney CC. 1998. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279:1643-1650. (Pubitemid 28248591)
29. Shao Q, Shen LH, Hu LH, Pu J, Qi MY, Li WQ, Tian FJ, Jing Q, He B. 2010. Nuclear, receptor Nur77 suppresses inflammatory response dependent on COX-2 in macrophages induced by oxLDL. J Mol Cell Cardiol 49:304-311.
30. Shen LH, Zhou L, Wang BY, Pu J, Hu LH, Chai DJ, Wang L, Zeng JZ, He B. 2008. Oxidized low-density lipoprotein induces differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Atherosclerosis 199:257-264.
31. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci 81:3883-3887. (Pubitemid 14087823)
32. Sundararaj KP, Samuvel DJ, Li Y, Nareika A, Slate EH, Sanders JJ, Lopes-Virella MF, Huang Y. 2008. Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation- mediated ERK activation. J Leukoc Biol 84:1120-1129.
33. Takemoto M, Liao JK. 2001. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719. (Pubitemid 34219772)
34. Taketa K, Matsumura T, Yano M, Ishii N, Senokuchi T, Motoshima H, Murata Y, Mitsuyama SK, Kawada T, Itabe H, Takeya M, Nishikawa T, Tsuruzoe K, Araki E. 2008. Oxidized low-density lipoprotein activates peroxisome proliferator- activated receptor-a (PPARa) and PPARg through MAPK-dependent COX-2 expression in macrophages. J Biol Chem 283:9852-9862.
35. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. 2006. Signaling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38:1654-1661.
36. Weber C, Schober A, Zernecke A. 2004. Chemokines: Key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24:1997-2008. (Pubitemid 39482421)